Gilead Sciences, Inc. (GILD.US) has initiated Phase III clinical trials for CD19/CD20 CAR-T cell therapy.

On March 18, the American clinical trial registration website showed that Kite Pharma, a subsidiary of Gilead Sciences, Inc. (GILD.US), initiated the first Phase III clinical trial of KITE-753. KITE-753 is a dual-targeted autologous CAR-T cell therapy targeting CD19 and CD20. The study is a randomized, multicenter, open-label clinical trial (n=550) aiming to evaluate the efficacy and safety of KITE-753 compared to axicabtagene ciloleucel in the treatment of relapsed or refractory large B-cell lymphoma (LBCL) patients who have previously received frontline therapy. The primary endpoints of the study are the proportion of patients achieving complete remission (CR) by month 6 and event-free survival (EFS) within 36 months. Results showed that in the dose-3 cohort, 11 out of 14 patients who had not previously received CAR-T cell therapy achieved CR, with a CR rate of 79%; in the overall population, 14 out of 20 patients who had not previously received CAR-T cell therapy achieved CR, with a CR rate of 70%.